Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:
Takeda Pharmaceutical Ltd ADR (TAK)
Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Why Shares of Innate Pharma Jumped Thursday Motley Fool - Thu Jun 8, 12:06PM CDT

The company's collaboration agreement with Sanofi could soon pay off.

SNY : 51.24 (-0.58%)
TAK : 16.21 (+0.56%)
IPHA : 3.23 (-2.71%)
Healthy Returns: This A Rated Healthcare Stock Is a Must-Watch for May stocknews.com - Fri Apr 28, 1:59PM CDT

Given the pharmaceutical industry’s robust growth prospects, drug-maker Neurocrine Biosciences’ (NBIX) stock is worth watching ahead of its first-quarter earnings next week. Read on… Investors...

NBIX : 93.39 (-0.68%)
NVO : 158.05 (-0.88%)
NVS : 100.93 (+0.28%)
TAK : 16.21 (+0.56%)
Is Your Portfolio Healthy? Don't Touch This Stock With a Ten-Foot Pole! stocknews.com - Thu Apr 27, 10:14AM CDT

Amidst lingering economic uncertainties, pharma contract development company Avid Bioservices (CDMO) has been flashing red flags with deteriorating financial results in the last reported quarter and bleak...

CDMO : 16.66 (-2.69%)
NVO : 158.05 (-0.88%)
NVS : 100.93 (+0.28%)
TAK : 16.21 (+0.56%)
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis Business Wire - Thu Apr 27, 7:00AM CDT

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational...

TAK : 16.21 (+0.56%)
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday Motley Fool - Tue Apr 25, 10:20AM CDT

The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.

AMGN : 218.76 (-0.91%)
GSK : 34.76 (+0.12%)
TAK : 16.21 (+0.56%)
ARWR : 35.32 (-1.06%)
This Supercharged Dividend King Stock Might Soon Run Out of Steam Motley Fool - Tue Apr 25, 8:45AM CDT

Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.

JNJ : 160.01 (-0.16%)
PFE : 38.97 (-0.31%)
BMY : 64.80 (-0.78%)
TAK : 16.21 (+0.56%)
GILD : 78.12 (-0.36%)
VRTX : 334.11 (+0.46%)
ABBV : 138.18 (+0.39%)
ABT : 101.69 (+0.90%)
MRK : 110.71 (+0.35%)
RXDX : 198.99 (+0.01%)
1 Pharma Stock You'll Regret Not Buying Earlier stocknews.com - Thu Apr 20, 10:43AM CDT

The long-term prospects of Merck (MRK) look bright due to its latest acquisitions and solid drug pipeline. Therefore, investing in this stock could help generate substantial returns in the long run. Keep...

IMGO : 36.01 (+0.03%)
JNJ : 160.01 (-0.16%)
MRK : 110.71 (+0.35%)
NVO : 158.05 (-0.88%)
RXDX : 198.99 (+0.01%)
TAK : 16.21 (+0.56%)
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children Business Wire - Tue Apr 11, 7:00AM CDT

Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary...

TAK : 16.21 (+0.56%)
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners Business Wire - Mon Apr 3, 7:30AM CDT

Takeda ( TSE:4502/NYSE:TAK ) today announced that 21 new U.S. non-profit organizations have received grants as part of the company’s $19.5 million commitment to its FY2022 Corporate Social Responsibility...

TAK : 16.21 (+0.56%)
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? Zacks - Thu Mar 30, 8:40AM CDT

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

TAK : 16.21 (+0.56%)

Barchart Exclusives

Coffee – A Bullish Trend After the Correction Barchart - Sat Jun 10, 9:40AM CDT
Soft commodities have been the leading sector of the raw materials asset class in 2023. In 2022, coffee and cotton futures reached over decade highs in February and May. The prices have come down from the 2022 highs, but nearby Arabica coffee futures have made higher lows since the October 2022 low. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot